Fixed-Dose Macitentan/Tadalafil Combo Gets FDA Approval for PAH

(MedPage Today) -- FDA approved macitentan/tadalafil (Opsynvi) as the first single-tablet combination therapy targeting multiple pathways for pulmonary arterial hypertension (PAH), Johnson & Johnson announced. The fixed-dose combination of...
Source: MedPage Today Public Health - Category: American Health Source Type: news